Numerai GP LLC Makes New Investment in Zoetis Inc. (NYSE:ZTS)

Numerai GP LLC purchased a new position in Zoetis Inc. (NYSE:ZTS) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 7,513 shares of the company’s stock, valued at approximately $1,224,000.

Several other hedge funds and other institutional investors have also made changes to their positions in ZTS. Vanguard Group Inc. grew its stake in Zoetis by 0.3% in the 4th quarter. Vanguard Group Inc. now owns 41,366,877 shares of the company’s stock worth $6,739,905,000 after acquiring an additional 120,158 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Zoetis by 1.8% in the 4th quarter. Geode Capital Management LLC now owns 10,617,897 shares of the company’s stock worth $1,726,075,000 after purchasing an additional 190,137 shares in the last quarter. Polen Capital Management LLC grew its stake in Zoetis by 17.5% during the 4th quarter. Polen Capital Management LLC now owns 7,483,194 shares of the company’s stock worth $1,219,237,000 after buying an additional 1,116,541 shares during the last quarter. Wellington Management Group LLP increased its position in Zoetis by 78.5% during the 4th quarter. Wellington Management Group LLP now owns 6,958,543 shares of the company’s stock valued at $1,133,755,000 after buying an additional 3,059,255 shares in the last quarter. Finally, Northern Trust Corp increased its position in Zoetis by 13.3% during the 4th quarter. Northern Trust Corp now owns 6,426,394 shares of the company’s stock valued at $1,047,052,000 after buying an additional 755,893 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Insider Transactions at Zoetis

In related news, Director Willie M. Reed sold 1,210 shares of Zoetis stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total value of $201,029.40. Following the sale, the director now directly owns 11,245 shares in the company, valued at approximately $1,868,244.30. The trade was a 9.71% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Roxanne Lagano sold 326 shares of the business’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $170.00, for a total value of $55,420.00. Following the sale, the executive vice president now owns 15,781 shares of the company’s stock, valued at approximately $2,682,770. This trade represents a 2.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.16% of the company’s stock.

Zoetis Price Performance

Shares of Zoetis stock opened at $160.43 on Wednesday. The firm has a market cap of $71.42 billion, a PE ratio of 29.33, a P/E/G ratio of 2.78 and a beta of 0.94. Zoetis Inc. has a twelve month low of $139.70 and a twelve month high of $200.33. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. The business has a 50-day moving average price of $157.03 and a 200 day moving average price of $165.79.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Tuesday, May 6th. The company reported $1.48 EPS for the quarter, topping the consensus estimate of $1.40 by $0.08. The company had revenue of $2.22 billion during the quarter, compared to analyst estimates of $2.20 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The firm’s revenue was up 1.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.38 EPS. Sell-side analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ZTS has been the subject of several recent analyst reports. UBS Group lowered their price target on Zoetis from $189.00 to $170.00 and set a “neutral” rating for the company in a report on Wednesday, May 7th. StockNews.com raised shares of Zoetis from a “hold” rating to a “buy” rating in a research report on Friday, March 7th. Morgan Stanley dropped their target price on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a research report on Friday, February 14th. Barclays upped their price target on shares of Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a research note on Friday, February 14th. Finally, Stifel Nicolaus lowered their price objective on shares of Zoetis from $180.00 to $165.00 and set a “buy” rating for the company in a research note on Monday, April 14th. One research analyst has rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $212.75.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.